bullish
Samsung Biologics Offering: Deal Summary & Trading Dynamics
369 Views31 Jan 2022 03:12
Samsung Biologics announced that it would purchase all of Samsung Bioepis shares owned by Biogen. So, it also announced a ₩3T rights offering. This post has the offering details and trading dynamics.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Samsung Biologics: Post-Offering Trading Dynamics on Potential Overhang12 Apr 2022
- Samsung Biologics Contract Manufacturing Deal with Moderna for COVID-19 Vaccines: Key Takeaways14 May 2021
- Samsung Biologics CMO Deal Noise & Samsung C&T Synthetic Subsidiary Stub Trade13 May 2021
- Stub Trade on Samsung C&T with BioLogics as a Sole Pair Partner04 Oct 2018
x